Safety of Single Aminoglycoside Dose among patient with chronic kidney disease in the Emergency Department (SAD-ED).

The Occurrence of AKI with Single Aminoglycoside Dose in the Emergency Department (SAD-ED) study in Patients with Chronic Kidney Disease: retrospective cohort study.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12625000195459

Enrollment

660

Registered

2025-02-20

Start date

2024-07-31

Completion date

2024-08-30

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The research project aims to determine the safety of commonly used antibiotics in emergency departments among patient with and without chronic kidney disease, to determine if these antibiotics (gentamicin, tobramycin and amikacin) increase the risk of acute kidney injury in patients with chronic kidney disease.

Interventions

This is a retrospective study of all ED patients who have received a single-dose IV aminoglycoside (gentamicin, tobramycin, amikacin) irrespective of the dose given. All data will be extracted of existing medical records. Primary study outcome is the proportion of patients with acute kidney injury (AKI) among individuals with CKD compared to those without CKD. Data will be collected for patients treated at study site between 2019 after EMR implementation up to July 2024.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

- Patients with CKD (eGFR < 60mL/min) who have received a single dose of an aminoglycoside (tobramycin, amikacin, gentamicin) irrespective of dose within the Emergency Departments across Monash Health (Monash Medical Centre Clayton, Dandenong, Casey, Victorian Heart Hospital). The identification of CKD will be based on KDIGO guidelines: GFR <60 mL/min/1.73m2 (GFR categories G3a–G5) for a minimum of 3 months.11

Exclusion criteria

- Patients who received multiple doses of aminoglycosides. - Patients without baseline creatinine levels. - Patients without weight records. - Patients on haemodialysis.

Outcome results